Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares OutstandingShares Outstanding
Ratios

Autolus Therapeutics (AUTL) Leases (2019 - 2025)

Autolus Therapeutics' Leases history spans 7 years, with the latest figure at $64.9 million for Q4 2025.

  • For Q4 2025, Leases rose 17.01% year-over-year to $64.9 million; the TTM value through Dec 2025 reached $64.9 million, up 17.01%, while the annual FY2025 figure was $64.9 million, 17.01% up from the prior year.
  • Leases reached $64.9 million in Q4 2025 per AUTL's latest filing, up from $56.6 million in the prior quarter.
  • In the past five years, Leases ranged from a high of $64.9 million in Q4 2025 to a low of $13.2 million in Q3 2022.
  • Average Leases over 5 years is $44.6 million, with a median of $56.2 million recorded in 2025.
  • Peak YoY movement for Leases: crashed 63.64% in 2021, then surged 348.83% in 2023.
  • A 5-year view of Leases shows it stood at $18.8 million in 2021, then grew by 23.62% to $23.2 million in 2022, then skyrocketed by 161.92% to $60.8 million in 2023, then dropped by 8.71% to $55.5 million in 2024, then increased by 17.01% to $64.9 million in 2025.
  • Per Business Quant, the three most recent readings for AUTL's Leases are $64.9 million (Q4 2025), $56.6 million (Q3 2025), and $58.6 million (Q2 2025).